Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVTX 009

Next Previous
Drug Profile

AVTX 009

Alternative Names: AVTX-009; FL-101; Fl101; IL-1β antibody - Eli Lilly; LY 2189102

Latest Information Update: 13 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Avalo Therapeutics; Eli Lilly and Company; Flame Biosciences
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hidradenitis suppurativa
  • Discontinued Cardiovascular disorders; Non-small cell lung cancer; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 13 Nov 2025 Avalo Therapeutics plans a phase III trial for hidradenitis suppurativa
  • 29 Oct 2025 Avalo Therapeutics completes enrolment in the phase II LOTUS trial in Hidradenitis suppurativa in USA, Australia, Canada, Bulgaria, Czech Republic, France, Germany, Italy, Poland, Slovakia, Spain and Turkey (SC) (NCT06603077)
  • 17 Apr 2013 Discontinued - Phase-I for Cardiovascular disorders in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top